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Summary
The risk of type 2 diabetes among obese adults who are metabolically healthy has
not been established. We systematically searched Medline (1946–August 2013)
and Embase (1947–August 2013) for prospective studies of type 2 diabetes
incidence (defined by blood glucose levels or self-report) among metaboli-
cally healthy obese adults (defined by body mass index [BMI] and normal
cardiometabolic clustering, insulin profile or risk score) aged ≥18 years at base-
line. We supplemented the analysis with an original effect estimate from the
English Longitudinal Study of Ageing (ELSA), with metabolically healthy obesity
defined as BMI ≥ 30 kg m−2 and <2 of hypertension, impaired glycaemic control,
systemic inflammation, adverse high-density lipoprotein cholesterol and adverse
triglycerides. Estimates from seven published studies and ELSA were pooled using
random effects meta-analyses (1,770 healthy obese participants; 98 type 2 diabe-
tes cases). The pooled adjusted relative risk (RR) for incident type 2 diabetes was
4.03 (95% confidence interval = 2.66–6.09) in healthy obese adults and 8.93
(6.86–11.62) in unhealthy obese compared with healthy normal-weight adults.
Although there was between-study heterogeneity in the size of effects (I2 = 49.8%;
P = 0.03), RR for healthy obesity exceeded one in every study, indicating a
consistently increased risk across study populations. Metabolically healthy obese
adults show a substantially increased risk of developing type 2 diabetes compared
with metabolically healthy normal-weight adults. Prospective evidence does not
indicate that healthy obesity is a harmless condition.
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Introduction
The global burden of type 2 diabetes is building dramati-
cally, with upwards of 370 million people estimated to have
diabetes; half of whom may be unaware of their condition
(1). Obesity is a well-established risk factor for type 2
diabetes (2). Although histological characteristics of adi-
posity play a direct role (3), much of the increased risk for
diabetes among the obese is thought to stem from the
underlying cardiometabolic abnormalities associated with
excess fat, such as islet beta-cell dysfunction, insulin resist-
ance, hyperglycaemia (3) and high chronic systemic inflam-
mation (4,5). Other contributing factors may include
higher levels of visceral fat (6), an energy-dense/nutrient-
poor diet including excessive sugar intake (7–9), and
physical inactivity (10,11) along with genetic, ethnic and
socioeconomic susceptibilities (12,13).
However, not all obese individuals seem to carry such
risk. Nearly one-third of obese adults in the general popu-
lation are considered metabolically healthy (14,15) and
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display favourable levels of biological factors relevant to
type 2 diabetes development. These include normal insulin
sensitivity, normoglycaemia, low inflammation (16,17) and
higher cardiorespiratory fitness (18). It remains unclear
if obese adults who are metabolically healthy also face
an increased risk for type 2 diabetes over time. Given the
increasing prevalence of obesity worldwide (19), a better
understanding of the health consequences facing its distinct
phenotypes would benefit both public health and clinical
practice, as well as support more efficient strategies for type
2 diabetes prevention and management.
To facilitate this, the objective of this study was to syn-
thesize existing prospective evidence on the risk of incident
type 2 diabetes for metabolically healthy obese adults in a
meta-analysis, supplemented by original individual-level
data obtained from a nationally representative sample of
older adults in England.
Methods
Meta-analysis of published cohort studies
Data sources and searches
A meta-analysis was conducted according to the
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) criteria (20). An OvidSP-led systematic search
of Medline (date range: from 1946 to August 2013) and
Embase (date range: from 1947 to August 2013) was per-
formed in August 2013 by JAB. Truncated search terms
included ‘obese’, ‘body mass index’, ‘metabolic’, ‘diabetes’,
‘type 2’, ‘risk’ and ‘incidence’. No language restrictions
were applied.
Study selection
JAB and MH independently screened search results and
agreed on studies to be included. Abstracts were scanned,
and references within relevant papers were hand-searched
for additional works. Studies were eligible for inclusion
in the meta-analysis if they met the full pre-specified cri-
teria for exposure (metabolically healthy obesity defined
by body mass index (BMI) and normal cardiometabolic
clustering, insulin profile or risk score), outcome (type 2
diabetes incidence defined by blood glucose levels or self-
report), population (adults aged ≥18 years at baseline) and
study design (original prospective estimation).
Data extraction and quality assessment
As estimates may be presented at more than one stage
of statistical adjustment, we elected to use fully adjusted
estimates for analyses, as these were more likely to be the
closest approximations of true study effects and offer more
comparability between studies. Study quality was assessed
according to the rigor of the study’s exposure, outcome
and model adjustment strategy. Regarding the exposure,
2 points were assigned if the study considered metabolic
clustering and 1 point if the study considered insulin profile
alone. For the outcome, 2 points were assigned if the diag-
nosis was based upon an objective clinical measurement
(i.e. fasting plasma glucose), and 1 point if the diagnosis
was based only upon self-report. Based upon the suggested
importance in the literature, studies were assigned 1 point
if they considered each of the following relevant covariates:
family history of diabetes, ethnicity, alcohol consumption,
smoking status, physical activity/cardiorespiratory fitness,
dietary sugar intake and socioeconomic status. Studies
were therefore scored out of 11 points, with higher scores
reflecting better study quality.
The English Longitudinal Study of Ageing
We supplemented studies identified through the literature
search with individual-level data from the English Longi-
tudinal Study of Ageing (ELSA). ELSA is an ongoing cohort
of a nationally representative sample of men and women
born on or before 29 February 1952 living in private
households in England (21). The sample was drawn using
multistage stratified probability sampling with postcode
sectors selected at the first stage and household addresses
selected at the second stage. Data from wave 2 (2004–05)
when participants were 52 years or older were used as the
baseline. Participants gave full informed written consent
to participate in the study and ethical approval was
obtained from the London Multi-Centre Research Ethics
Committee.
Nurses collected anthropometric data (weight and
height), measured blood pressure (BP) and took blood
samples, as previously described (22). Blood samples
were analysed for C-reactive protein (CRP), high-density
lipoprotein (HDL)-cholesterol, triglycerides and glycated
haemoglobin (HbA1c). BMI was calculated using the
standard formula (weight [kilograms]/height [meters]
squared). Normal-weight (BMI < 25 kg m−2), overweight
(BMI 25 < 30 kg m−2) and obese (BMI ≥ 30 kg m−2) were
defined using conventional criteria. ‘Metabolically healthy’
status was defined as <2 of the following metabolic risk
factors: hypertension (clinic BP > 130/85 mmHg, or hyper-
tension diagnosis, or use of anti-hypertensive medication),
impaired glycaemic control (HbA1c > 6.0%), systemic
inflammation (CRP ≥ 3 mg L−1), adverse HDL-cholesterol
(<1.03 mmol L−1 in men and <1.30 mmol L−1 in women)
and adverse triglycerides (≥1.7 mmol L−1), based upon
comprehensive criteria (14) that have been previously
employed in ELSA (22). Participants were categorized
into six groups: ‘metabolically healthy normal-weight’;
‘metabolically unhealthy normal-weight’; ‘metabolically
healthy overweight’; ‘metabolically unhealthy overweight’;
‘metabolically healthy obese’; and ‘metabolically unhealthy
obese’.
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Type 2 diabetes was recorded from self-reported phy-
sician diagnosis, which has been previously validated in
ELSA (23). Incident cases of diabetes were recorded over
waves 3 (2006/2007), 4 (2008/2009) and 5 (2010/2011),
thus follow-up ranged from 2 to 6 years (mean = 5.9 years).
Participants with type 2 diabetes at baseline were excluded
from analyses.
Demographic and health-related questions included
cigarette smoking (current, previous or non-smoker), the
frequency of participation in vigorous, moderate and light
intensity physical activities (more than once per week, once
per week, one to three times per month, hardly ever), and
frequency of alcohol intake (daily, 5–6/week, 3–4/week,
1–2/week, 1–2/month, once every couple of months, 1–2/
year, never). Depressive symptoms were assessed using
the 8-item Centre of Epidemiological Studies Depression
scale. Wealth served as a comprehensive measure of socio-
economic status, calculated as net of debt and included the
total value of the participant’s home (excluding mortgage);
financial assets such as savings, business assets; and phy-
sical wealth such as artwork or jewellery.
Data synthesis and analysis
In analysing data from ELSA, we used Cox proportional
hazard models to compute hazard ratios (HRs) with
accompanying 95% confidence intervals (CIs) for the asso-
ciation of metabolic health/obesity categories with diabe-
tes. The proportional hazard assumption was examined
by comparing the cumulative hazard plots grouped on the
various exposure variables, although no appreciable viola-
tions were noted. Years of follow-up were the time scale,
and for participants with no record of an event, the data
were censored at wave 5 (maximum 6 years follow-up).
Models were adjusted for age, sex, and behavioural and
socio-demographic covariates, including smoking, alcohol,
physical activity, depressive symptoms and wealth quintile.
This modelling strategy was planned a priori based upon
existing evidence linking these covariates with obesity and
diabetes (24–27). Analyses were conducted using SPSS,
version 21 (SPSS Inc., Chicago, IL, USA).
We used meta-analysis to synthesize data from published
studies identified through the literature search and ELSA.
Natural variation in study effects was expected due to
differences in such factors as obesity phenotype definition,
sampling procedure, statistical adjustment strategy and
sample demographics. A random effects model was there-
fore employed to estimate the mean of the distribution
of effects, with the I2 statistic used to describe the percentage
of between-study heterogeneity (28). Odds ratios (ORs),
HRs and relative risk (RR) ratios were pooled and log-
transformed for analyses. Random effects meta-regression
was planned a priori to examine the extent to which age,
ethnicity, duration of follow-up and study quality including
phenotype criteria explain any observed between-study het-
erogeneity in effects. The meta-analysis was performed
using Stata 12 (StataCorp, College Station, TX, USA).
Results
Literature search of published studies
As shown in Fig. 1, the initial search of Medline and
Embase retrieved 1,068 results. Two additional studies
were identified through other sources (29,30). After remov-
ing duplications, 168 studies remained, 159 of which were
excluded due to irrelevant exposure or outcome based
1,068 records identified 
through database searching
168 records after duplicates removed
168 records screened
7 studies + ELSA = 
8 studies included in 
meta-analysis
2 additional records identified 
through other sources
9 full-text articles 
assessed for eligibility
159 records excluded due to
irrelevant exposure or outcome
based upon abstract screening
Original data 
from ELSA 
2 excluded for assessing participants 
< 18 years old at baseline
Figure 1 Outline of the systematic study
selection process for the meta-analysis.
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upon abstract screening. Nine studies were identified after
screening as potentially relevant, and full-text articles were
assessed for eligibility. Of these, two studies were excluded
for assessing participants less than 18 years of age at base-
line (31,32). Seven published studies therefore met our
full criteria for inclusion (29,30,33–37). Hand-searching
through reference lists within those seven included studies
identified six additional potentially relevant studies, but
none of these met the full inclusion criteria. For instance,
one study assessed cross-sectional type 2 diabetes preva-
lence but not prospective incidence (38).
The English Longitudinal Study of Ageing
The sample comprised 3,066 individuals (aged 64.6 ± 8.5
years, 43.3% men). Compared with the metabolically
unhealthy obese and non-obese, metabolically healthy
obese participants were on average younger, less likely to be
smokers and had intermediate levels of risk factors (see
Supporting Information Appendix S1). The metabolically
healthy obese had lower BMI than their unhealthy obese
counterparts.
Over 6 years of follow-up, there were 138 incident dia-
betes cases. Relative to healthy normal-weight participants,
the highest risk of incident diabetes was observed in the
unhealthy obese, followed by the unhealthy overweight
and unhealthy normal-weight (Supporting Information
Appendix S2). The metabolically healthy obese were also at
elevated risk (HR = 8.6; 95% CI = 2.4–30.4) after adjust-
ment for behavioural and socio-demographic covariates.
The unhealthy obese had a substantially higher risk of
diabetes than the metabolically healthy obese participants
despite adjustment for all covariates, including wealth
and health behaviours (HR = 23.5; 95% CI = 7.3–75.6).
The metabolically unhealthy overweight (HR = 16.7; 95%
CI = 5.2–54.2) and the unhealthy normal-weight (HR =
9.9; 95% CI = 2.9–36.7) were also at higher risk of inci-
dent diabetes than the metabolically healthy normal-weight
participants. The pattern of results across groups remained
the same when metabolically healthy phenotypes were
defined as having zero metabolic abnormalities (Supporting
Information Appendix S3).
Meta-analysis of published cohort studies and
English Longitudinal Study of Ageing
Including ELSA, a total of eight studies contributed to
the meta-analysis. Two studies reported the effect estimates
for type 2 diabetes separately by sex (30,34), and were
presented accordingly. The studies included in the meta-
analysis represented a geographically diverse set of popu-
lations (Table 1); however, ethnic composition was not
specifically reported in any study. Age at baseline ranged
from 18 years in three studies (29,34,37) to 99 years in
ELSA. All studies defined metabolic health based upon
metabolic clustering, with the least comprehensive measure
considering only insulin resistance, triglycerides and fasting
glucose (37). All studies used an objective fasting blood
or plasma glucose measure to diagnose incident type 2
diabetes except for ELSA, which used self-reported physi-
cian diagnosis. Average length of follow-up ranged from
5 years in Kim et al. (35) to 20 years in Arnlov et al. (33).
The reference category was a metabolically healthy
non-obese group in all studies; however, specific cut-offs
varied, with one study using a broad ‘non-obese’ group
as the reference (BMI < 30 kg m−2) (37), whereas ELSA
and others excluded overweight individuals from the refer-
ence group by setting the cut-off as BMI < 25 kg m−2
(30,33,35,36). Still others excluded both overweight and
underweight adults in their reference group (29,34).
Overall, there appeared to be wide variability in effect
estimates for type 2 diabetes, ranging from 2.09 (95%
CI = 0.87–5.05) in Appleton et al. (29) to 14.60 (95%
CI = 3.23–65.50) in Hwang et al. (women) (34). However,
all RR estimates exceeded one, with none reporting a
reduced risk of type 2 diabetes in metabolically healthy
obese adults. Figure 2 presents results of the random effects
meta-analysis, which modelled the log of ORs, risk ratios,
HR and CIs pooled from respective studies. The summary
RR was 4.03 (95% CI = 2.66–6.09), suggesting that the
healthy obese had over four times higher risk of incident
type 2 diabetes than the healthy normal-weight group. In
comparison, the corresponding pooled RR in the metaboli-
cally unhealthy obese group was 8.93 (95% CI = 6.86–
11.62) (Fig. 3). There was variability in the effect size
(I2 statistic of 49.8%; P = 0.03), although RRs for healthy
obesity exceeded one in every study. We performed meta-
regression to test the extent to which specific study-level
factors explained the between-study heterogeneity in
effects, chosen a priori (39) as age, ethnicity, length of
follow-up and study quality. However, no study reported
the ethnic composition of their analytical sample, prevent-
ing us from exploring contributions of that factor. Neither
study quality (P = 0.18), length of follow-up (P = 0.34) nor
age (P = 0.99) significantly predicted heterogeneity in effect
estimates.
Discussion
In the identified studies, metabolically healthy obese adults
showed, with few exceptions, a substantially increased risk
for developing type 2 diabetes compared with metaboli-
cally healthy normal-weight adults. When prospective evi-
dence was synthesized in a random effects meta-analysis
(average length of follow-up ranging from 5 years in Kim
et al. (35) to 20 years in Arnlov et al. (33)), metaboli-
cally healthy obese adults demonstrated over four times
greater risk of developing type 2 diabetes over time when
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Figure 2 Metabolically healthy obesity and adjusted relative risk (RR) of incident type 2 diabetes.
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Figure 3 Metabolically unhealthy obesity and adjusted relative risk (RR) of incident type 2 diabetes.
Note: Analysis excludes Hwang et al. (2012) (34) as authors considered metabolically healthy participants at baseline only.
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compared to healthy normal weight adults; albeit the risk
among the healthy obese was approximately half that of
the unhealthy obese group.
Our original analysis of older English adults suggests
that after adjustment for covariates, the healthy obese were
still at significantly increased risk for incident type 2 dia-
betes, albeit to a lesser extent than their unhealthy obese
counterparts. These findings are consistent with other
studies accounting for similar baseline covariates (30,34),
and the commonly observed trend of increasing risk across
BMI groups further supports body mass as an important
risk factor. Healthy obese adults did not show a statistically
significant increased risk of type 2 diabetes compared with
healthy normal-weight adults in an early American study
(36), and in a more recent Australian study (29), although
in both of these studies, the RR exceeded one.
We observed heterogeneity in effects of healthy obesity
between studies, with estimates ranging from 2.09 (95%
CI = 0.87–5.05) in Appleton et al. (29) to 14.60 (95%
CI = 3.23–65.50) in Hwang et al. (women) (34). There was
no evidence to suggest that this was explained by differ-
ences in participant’s age, duration of follow-up or study
quality. Such heterogeneity might stem from variations
in phenotype criteria employed across studies, such as
inconsistencies in metabolic factors considered and specific
cut-points used. However, despite this heterogeneity, all
estimates appeared to be in the same direction, with no
studies reporting a reduced risk of incident type 2 diabetes
for healthy obese adults.
Large CIs were observed across several studies, point-
ing to the relatively large degree of uncertainly attached
to respective estimates. While sample numbers of meta-
bolically healthy obese individuals are often small in
population-based prospective studies (ranging from n = 15
in Hwang et al. [men] (34) to several hundred in others),
this phenotype does not represent a small segment of the
population. Nearly one-third of obese adults in the general
population are thought to be metabolically healthy (14,15),
which, as the proportion of obese adults increases, will
continue to represent a substantial number of people in
both relative and absolute terms. Small sample sizes in
previous studies may reflect the research challenges associ-
ated with studying repeat clinical characteristics over long
periods of time.
Type 2 diabetes is often regarded as a state of chronic
fuel surfeit (40), and as such, dietary factors are expected to
play a central role in disease risk. Despite this, no studies
considered the influence of dietary factors, such as sugar
intake, on the risk of type 2 diabetes for healthy obese
adults. Likewise, only half of the studies considered any
indicator of cardiorespiratory fitness or physical activity,
which are also important protective factors against type
2 diabetes development (10,11). Additionally, a limited
range of prescription drugs were considered in statistical
adjustments. Whereas the healthy obese phenotype is often
defined according to use of anti-hyperglycaemic or anti-
hypertensive medications, the use of statins was considered
in only two studies (29,30). Other prescription drug use or
dietary interventions may help account for their apparent
metabolic protection and should be considered in more
depth in future work.
Potential confounding effects of environmental factors
are also notably absent from the evidence base. For
example, living in a deprived residential environment is
associated with an increased risk of obesity and type 2
diabetes (41–43), which may be explained in part by
increased accessibility of energy-dense/nutrient-poor foods,
decreased opportunities for recreational or transport-based
physical activity (44), and psychosocial stress (45,46).
Environmentally distributed chemicals, known as persis-
tent organic pollutants, have also been positively associated
with the risk of type 2 diabetes among obese and non-obese
adults in a dose-response manner (47), and thus could
potentially confound associations between obesity and
incident type 2 diabetes. Until such factors are adequately
controlled for, it remains difficult to separate their effects
from direct effects of healthy obesity, and thus make firm
conclusions regarding chronic disease risk.
A critical factor to consider when estimating future
disease risk in the healthy obese group is the stability of
metabolic health over time – i.e. whether metabolically
healthy obese adults actually remain metabolically healthy
for the duration of follow-up, or whether they transition
into an unhealthy state before outcomes are assessed.
Evidence on long-term phenotypic stability as it relates
to diabetes risk is currently limited. However, one recent
study found that obese adults who maintained metabolic
health for up to 10 years showed no increased risk for type
2 diabetes incidence (29). Sustained metabolic health was
associated with younger age and lower levels of abdominal
adiposity as indicted by lower waist circumferences (29).
The accuracy of diabetes risk estimates would be improved
by paying closer attention to stability and change in
metabolic health over time in both obese and non-obese
populations.
It is also important to note that despite an increased risk
for incident type 2 diabetes compared with healthy normal-
weight adults, healthy obese adults often show a lower risk
for type 2 diabetes than metabolically unhealthy groups of
any body mass. For example, in our analysis of ELSA, the
healthy obese demonstrated an 8.6 (95% CI = 2.4–30.4)
times higher risk of developing diabetes, whereas the
unhealthy normal-weight showed a higher risk for disease
development at 9.9 (95% CI = 2.9–36.7) after adjusting for
baseline socioeconomic, health and behavioural covariates.
The increased risk in metabolically unhealthy normal-
weight adults is apparent when the phenotype is defined
by either metabolic clustering or insulin resistance only
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(36). Greater attention should be paid to unhealthy
normal-weight adults as they represent a sizable proportion
of the general population and may be less targeted for
interventions.
Intriguingly, standard weight-loss interventions among
the healthy obese have experienced limited success. For
example, healthy obese adults showed no improvement
in individual metabolic risk factors such as blood lipids,
inflammatory markers (48) and insulin sensitivity (49)
in response to diet- and/or exercise-based interventions,
whereas others reported detrimental effects such as
decreased insulin sensitivity (50). Another study reports
that healthy obese adults who lost fat mass up to the point
of resistance to further weight-loss experienced notable
adverse physiological effects including worsened appetite
regulation, decreased energy expenditure and increased
depressive symptoms (51), all of which may promote
weight regain. It remains unknown whether such adverse
physiological effects are characteristic of the entire healthy
obese population or only a subgroup, as no studies to date
have utilized nationally representative data. ‘Weight loss’ is
also a crude metric in light of emerging evidence show-
ing more favourable fat distribution in the healthy obese,
characterized by lower visceral fat and greater thigh sub-
cutaneous fat (52), along with favourable adipose tissue
function and morphology (53). Targeted fat loss may there-
fore be more appropriate for healthy obese adults. Indeed,
several studies report reductions in visceral fat among
healthy obese men and women (49,54,55), whereas others
show increased levels of cardiorespiratory fitness (54),
improved insulin sensitivity and improved fasting insulin
(55), all of which may contribute to a lower risk of type 2
diabetes.
Strengths and limitations
This is the first meta-analysis to summarize the risk of
incident type 2 diabetes in the metabolically healthy obese
phenotype. These data will help establish whether an
apparently healthy subset of the obese population faces
an increased risk for metabolic disease. We had the advant-
age of supplementing this meta-analysis with an original
estimate from a nationally representative sample of older
adults in England, affording a larger sample size and a
more complete view of diabetes risk across adulthood. This
study also explored the potential impact of relevant con-
founding factors, such as age, duration of follow-up and
study quality using meta-regression.
The between-study heterogeneity in effects observed may
reflect differences in study characteristics such as pheno-
type definitions, length of follow-up, statistical adjustment
strategies, as well as differences inherent to populations
such as age, ethnicity or obesity management strategies
such as lifestyle interventions or prescription drug use.
However, with the small number of studies currently
available, and with each measuring a different population,
numbers within each age or ethnic group would likely be
too small to draw meaningful conclusions about the source
of heterogeneity. A standard definition of what constitutes
‘metabolic health’ within obese populations would aid
efforts to understand differences in effects due purely to
specific demographic or lifestyle factors.
Conclusion
Metabolically healthy obese adults show a substantially
increased risk of incident type 2 diabetes compared with
metabolically healthy normal-weight adults. Existing pro-
spective evidence does not indicate that healthy obesity is a
harmless condition.
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